Introduction Advances have been made in positron emission tomography (PET) myocardial perfusion since the Food and Drug Administration (FDA) approved the use of flurpiridaz, which was shown effective in the detection of coronary artery disease (CAD) in two phase III trials, with a high diagnostic precision as compared with Single Photon Emission Computed Tomography (SPECT) scintigraphy.– Flurpiridaz is an injectable radiotracer, labeled with fluorine-18 (F-18), developed by GE HealthCare, that will be sold as “Flyrcado” in the United States from […]

Limitations The article offers an intriguing perspective, but further scientific validation is needed for broader acceptance in clinical practice. The connection between art and medical imaging is fascinating, yet requires more exploration to establish its practical relevance and impact on patient outcomes. […]

[…]

[…]

[…]